A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy

Ryo Kasahara, Takashi Kawahara, Shinji Ohtake, Yoko Saitoh, Sohgo Tsutsumi, Jun-ichi Teranishi, Yasuhide Miyoshi, Noboru Nakaigawa, Masahiro Yao, Kazuki Kobayashi, and Hiroji Uemura

1 Departments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan
2 Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan
3 Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Correspondence should be addressed to Takashi Kawahara; takashi_tk2001@yahoo.co.jp

Received 5 February 2017; Accepted 3 April 2017; Published 13 April 2017

Introduction. Gemcitabine and cisplatin (GC) is a gold-standard first-line systemic chemotherapy for advanced urothelial carcinoma (UC). However, it may cause severe adverse effects such as renal toxicity, gastrointestinal toxicity, and neurotoxicity. Sarcopenia is the age-related loss of skeletal muscle mass [5]. A correlation between sarcopenia and the oncological prognosis has been reported. In UC, several studies have noted that patients with sarcopenia had a greater incidence of complications and worse survival after radical cystectomy or chemotherapy. Our institute introduced gemcitabine and nedaplatin (GN) for UC patients with renal failure. We investigated whether the presence of sarcopenia predicted the prognosis of patients with advanced UC who were treated by GN chemotherapy.

Methods. A total of 27 patients (male, n = 21; female, n = 6) received GN therapy for metastatic UC from 2005 to 2016. The institutional review board of Yokohama City University Hospital approved this study. The psoas muscle index (PMI, cm²/m²) was calculated using this formula: right psoas muscle area (cm²)/the square of the body height (m²). The overall survival (OS) of the high PMI group (male: ≥2.49, female: ≥2.07) and low PMI group (male: <2.49, female: <2.07) was compared.

Results. Kaplan-Meier survival curves and a log-rank test revealed that the high PMI group had significantly better OS than the low PMI group (p = 0.015). The mean survival of the high and low PMI groups was 361 days and 223 days, respectively.

Conclusions. In the present study, we revealed that sarcopenia (a low psoas muscle volume) might be a predictive factor for poorer overall survival in patients with advanced urothelial carcinoma who are undergoing GN chemotherapy.

1. Introduction

Gemcitabine and cisplatin (GC) is a gold-standard first-line systemic chemotherapy for advanced urothelial carcinoma (UC). However, it may cause severe adverse effects such as renal toxicity, gastrointestinal toxicity, and neurotoxicity. Its nephrotoxic characteristic makes it particularly unsuitable for advanced UC patients because they may have either age-associated or postsurgical renal dysfunction. Instead, nedaplatin, a second-generation platinum complex with lower renal and gastrointestinal toxicity than cisplatin, can be used for patients with a marginal renal function [1–4].

Sarcopenia is the term used to describe the age-related loss of skeletal muscle mass [5]. A correlation between sarcopenia and the oncological prognosis has been reported in malignant melanoma, breast cancer, hepatocellular carcinoma, gastric cancer, and pancreatic cancer [6–10]. In urothelial carcinoma, several studies have noted that patients with sarcopenia have a greater incidence of complications and worse survival after radical cystectomy or chemotherapy [11–13]. Taguchi et al. reported that sarcopenia is associated with a significantly worse prognosis in metastatic UC patients who receive systemic chemotherapy [14]. However, no studies have reported whether sarcopenia can be used as a prognostic
Table 1: The clinical characteristics of the patients.

|                                      | Total (n = 27) | High PMI (n = 13) | Low PMI (n = 14) | p value |
|--------------------------------------|---------------|-------------------|-----------------|---------|
| Age (years)                          |               |                   |                 |         |
| <65                                  | 13 (48.1%)    | 7 (53.8%)         | 6 (42.9%)       | 0.568   |
| ≥65                                  | 14 (51.9%)    | 6 (46.2%)         | 8 (57.1%)       |         |
| Gender                               |               |                   |                 |         |
| Female                               | 6 (22.2%)     | 3 (23.1%)         | 3 (21.4%)       | 0.918   |
| Male                                 | 21 (77.8%)    | 10 (76.9%)        | 11 (78.6%)      |         |
| Creatinine clearance (mL/min.)       |               |                   |                 |         |
| <60                                  | 12 (44.4%)    | 6 (46.2%)         | 6 (42.9%)       | 0.8632  |
| ≥60                                  | 15 (55.6%)    | 7 (53.8%)         | 8 (57.1%)       |         |
| Cystectomy or nephroureterectomy     |               |                   |                 |         |
| Yes                                  | 16 (59.3%)    | 10 (76.9%)        | 6 (42.9%)       | 0.0719  |
| No                                   | 11 (40.7%)    | 3 (23.1%)         | 8 (57.1%)       |         |
| Response after 2 courses of GN therapy|              |                   |                 |         |
| CR and PR                            | 13 (48.1%)    | 10 (76.9%)        | 3 (21.4%)       | 0.0719  |
| SD and PD                            | 14 (51.9%)    | 6 (46.2%)         | 8 (57.1%)       |         |
| Adverse effects (grade ≥ 3)          |               |                   |                 |         |
| Neutropenia                          | 25 (92.6%)    | 12 (92.3%)        | 13 (92.9%)      | 0.9566  |
| Thrombocytopenia                     | 17 (63.0%)    | 8 (61.5%)         | 9 (64.3%)       | 0.6802  |
| Appetite loss or nausea              | 1 (3.7%)      | 1 (7.7%)          | 0 (0%)          | 0.2903  |

2. Materials and Methods

2.1. Patients. A total of 27 patients (male, n = 21; female, n = 6) received GN therapy for metastatic UC at Yokohama City University Hospital (Yokohama, Japan) from 2005 to 2016. All of the patients were Asian (Japanese). The institutional review board of Yokohama City University Hospital approved this study. The patients’ characteristics are summarized in Tables 1 and 2. Among these patients, 8 (29.6%) underwent radical cystectomy and 8 (29.6%) underwent nephroureterectomy prior to GN therapy. The mean age was 61.9 years (range: 38–73). The mean creatinine clearance (CCr) was 70.1 ml/min (range: 40.0–109.0). Twelve patients had kidney dysfunction (CCr ≤ 12 ml/min.), while 15 patients had an adequate renal function (CCr ≥ 60 ml/min.).

2.2. Drug Administration and the Evaluation of Responses. Patients received gemicitabine 1,000 mg/m² on days 1 and 8 plus nedaplatin 80 or 100 mg/m² on day 1. Dose modification was allowed depending on the patient’s general condition, CCr, and bone marrow suppression status. All patients received at least 2 cycles of GN chemotherapy. The tumor response was assessed after 2 cycles of GN chemotherapy according to the Response Evaluation Criteria in Solid Tumor (RECIST). Adverse effects were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Table 2: Locations of metastases and responses after two courses of GN therapy.

|              | CR-PR | SD | PD | Total |
|--------------|-------|----|----|-------|
| Lymph node   | 13 (59%) | 7 | 2 | 22    |
| Lung         | 4 (57%)  | 1 | 2 | 7     |
| Liver        | 2 (67%)  | 1 | 0 | 3     |
| Bone         | 0 (0.0%) | 2 | 0 | 2     |
| Local recurrence | 1 (17%) | 5 | 0 | 6     |
| Urethra      | 0 (0.0%) | 1 | 0 | 1     |

2.3. Clinical Assessments. The area of the right psoas muscle on axial CT was calculated at the level of the L3 before GN therapy. We previously examined the psoas muscle volume and surgical complications using right/left and L3 level/umbilicus. As the right psoas muscle volume showed the highest sensitivity; we used the right L3 level psoas volume for further assessments. The psoas muscle index (PMI, cm²/m²) was calculated using this formula: right psoas muscle area (cm²)/the square of the body height (m²). The overall survival (OS) of the high PMI group (male: ≥2.49, female: ≥2.07) and low PMI group (male: <2.49, female: <2.07) was compared. The raw data of psoas muscle area and body height are attached as Supplementary Material available online at [https://doi.org/10.1155/2017/7981549](https://doi.org/10.1155/2017/7981549).

2.4. Cut-Off Values. Due to the differences in the PMI values of male and female patients, we set the cut-off point for each gender. The median cut-off PMI values for males and females were 2.49 and 2.07, respectively (p = 0.026). There
advanced UC. Cisplatin binds to serum proteins easily; thus, it is thought that this characteristic of cisplatin is responsible for the severe adverse effects observed in cisplatin-based chemotherapy. Thus, other platinum complexes can be used to reduce the toxicity of chemotherapy. Carboplatin, a cisplatin analogue, shows improved toxicity and favorable anticancer efficacy. The response rate in patients with upper urinary tract UC is reported to be 18.4% [16]. Moreover, nedaplatin, a second-generation platinum complex, has been developed. Nedaplatin is associated with less renal toxicity and a lower incidence of gastrointestinal complications than cisplatin [1, 3]. Matsumoto et al. reported that GN therapy had greater efficacy against lung cancer in vivo than GC or gemcitabine and carboplatin [4]. In our institution, based on these merits, we have administered nedaplatin-based chemotherapy to patients with advanced UC and have demonstrated good results [1, 2].

Gemcitabine and platinum complex-based chemotherapy has improved the survival of patients with advanced UC. However, some patients show aggressive disease progression and die within a few months. Hence, we need reliable and convenient predictors of patients’ survival. Sarcopenia refers to the degenerative loss of skeletal muscle associated with aging, cachexia, and frailty—these conditions, termed geriatric syndrome, result from the age-related cumulative decline in the function of multiple organs [5]. Recently, sarcopenia has been reported as a predictive factor for various malignancies. For instance, sarcopenia is reported to be a useful predictor of cancer survival and the perioperative outcomes of melanoma, breast cancer, hepatocellular carcinoma, gastric cancer, and pancreatic cancer [6–10].

In UC, several studies have reported that sarcopenia is associated with an increased risk of perioperative complications and that it is correlated with a poor prognosis after radical cystectomy [11–13]. Taguchi et al. reported that sarcopenia was an independent predictor of a poor prognosis in patients with metastatic UC who underwent first-line systemic chemotherapy [14].

In previous studies on sarcopenia, dual-energy X-ray absorptiometry and a bioelectrical impedance analysis were used to calculate the skeletal muscle volume. However, these examinations are not performed in the routine medical care of patients with malignancies. We therefore used standard axial CT to calculate the psoas muscle volume. We then revealed that the PMI (calculated by the right-side psoas muscle area and height) can predict a patient’s overall survival. One limitation of this study is that it included both surgery and nonsurgery patients. Cystectomy and nephroureterectomy are important factors influencing both the OS and PFS. Our institution allocated patients to receive cystectomy or nephroureterectomy based on their age and performance status. Sarcopenia might have therefore influenced the outcomes of cystectomy and nephroureterectomy. Further studies are needed to corroborate our findings.

In the present study, our findings revealed that sarcopenia (a low psoas muscle volume) may be a predictive factor for poorer overall survival in patients with advanced urothelial carcinoma undergoing GN chemotherapy.
Data Access

Due to ethical restrictions, the raw data underlying this paper is available upon request to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest in association with the present study.

Authors’ Contributions

Ryo Kasahara and Takashi Kawahara conceived and designed the experiments. Ryo Kasahara and Takashi Kawahara analyzed data. Ryo Kasahara, Shinji Ohtake, Yoko Saitoh, Sohgo Tsutsumi, Jun-ichi Teranishi, Yasuhide Miyoshi, Noboru Nakaigawa, Masahiro Yao, Kazuki Kobayashi, and Hiroji Uemura performed the experiments. Ryo Kasahara and Takashi Kawahara wrote the paper.

Acknowledgments

This paper received grants from KAKENHI grants (16K20152) and Research Development Fund of Yokohama City University (no. WJ2810).

References

[1] T. Kawahara, H. Oshiro, Z. Sekiguchi et al., “High-grade invasive urothelial carcinoma with focal plasmacytoid differentiation successfully treated by transurethral resection followed by chemoradiotherapy,” International Journal of Urology, vol. 18, no. 12, pp. 851–853, 2011.

[2] S. Uemoto, Y. Miyoshi, Y. Yokomizo et al., “A case of salvage combination chemotherapy of gemcitabine plus nedaplatin for squamous cell carcinoma of the ureter,” Acta Urologica Japonica, vol. 52, no. 1, pp. 35–39, 2006.

[3] W. Cao, C. Xu, G. Lou et al., “A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer,” Japanese Journal of Clinical Oncology, vol. 39, no. 9, pp. 582–587, 2009.

[4] M. Matsumoto, Y. Takeda, H. Maki et al., “Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer,” Japanese Journal of Cancer Research, vol. 92, no. 1, pp. 51–58, 2001.

[5] A. J. Cruz-Jentoft, F. Landi, S. M. Schneider et al., “Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWG- SOP and IWGS),” Age and Ageing, vol. 43, no. 6, pp. 48–759, 2014.

[6] M. S. Sabel, J. Lee, S. Cai, M. J. Englesbe, S. Holcombe, and S. Wang, “Sarcopenia as a prognostic factor among patients with stage III melanoma,” Annals of Surgical Oncology, vol. 18, no. 13, pp. 3579–3585, 2011.

[7] E. Del Fabbro, H. Parsons, C. L. Warneke et al., “The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer,” Oncologist, vol. 17, no. 10, pp. 1240–1245, 2012.

[8] O. Mir, R. Coriat, B. Blanchet et al., “Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma,” PLoS ONE, vol. 7, no. 5, Article ID e35763, 2012.

[9] C.-L. Zhuang, D.-D. Huang, W.-Y. Pang et al., “Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: analysis from a large-scale cohort,” Medicine, vol. 95, no. 13, Article ID e364, 2016.

[10] J. K. Onesti, G. P. Wright, S. E. Kenning et al., “Sarcopenia and survival in patients undergoing pancreatic resection,” Pancreatology, vol. 16, no. 2, pp. 284–289, 2016.

[11] F. Wan, Y. Zhu, C. Gu et al., “Lower skeletal muscle index and early complications in patients undergoing radical cystectomy for bladder cancer,” World Journal of Surgical Oncology, vol. 12, no. 1, article 14, 2014.

[12] A. B. Smith, A. M. Deal, H. Yu et al., “Sarcopenia as a predictor of complications and survival following radical cystectomy,” Journal of Urology, vol. 191, no. 6, pp. 1714–1720, 2014.

[13] S. P. Psutka, A. Carrasco, G. D. Schmit et al., “Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality,” Cancer, vol. 120, no. 18, pp. 2910–2918, 2014.

[14] S. Taguchi, N. Akamatsu, T. Nakagawa et al., “Sarcopenia evaluated using the skeletal muscle index is a significant prognostic factor for metastatic urothelial carcinoma,” Clinical Genitourinary Cancer, vol. 14, no. 3, pp. 237–243, 2016.

[15] Y. Sasaki, T. Tamura, K. Eguchi et al., “Pharmacokinetics of (glycolato-0,01)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin,” Cancer Chemotherapy and Pharmacology, vol. 23, no. 4, pp. 243–246, 1989.

[16] H. Akaza, M. Hagiwara, N. Deguchi et al., “Phase II trial of carboplatin in patients with advanced germ-cell testicular tumors and transitional cell carcinomas of the urinary tract,” Cancer Chemotherapy and Pharmacology, vol. 23, no. 3, pp. 181–185, 1989.